GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine Menveo

GSK plc (GSK) announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of its meningococcal vaccine, Menveo (MenACWY) for active immunization in children aged two years, adolescents as well as adults.The single-vial, fully liquid presentation of Menveo is likely to simplify the vaccination process against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W and Y.The fully liquid presentation of the vaccine will help healthcare providers with a ...